Michael Henry Rosenbloom
Affiliation: HealthPartners Research Foundation
- A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein E4 carriers with mild-moderate Alzheimer's diseaseMichael H Rosenbloom
HealthPartners Center for Memory and Aging, Regions Hospital, 401 Phalen Blvd, Mail Stop 41104C, St Paul, MN, 55130, USA
CNS Drugs 28:1185-9. 2014..Furthermore, rapid-acting (RA) insulins may have superior therapeutic effects compared with regular insulin types...
- The functional neuroanatomy of decision-makingMichael H Rosenbloom
Center for Dementia and Alzheimer s Care, Department of Neurology, HealthPartners, St Paul, MN, USA
J Neuropsychiatry Clin Neurosci 24:266-77. 2012..Finally, clinical relevance of this circuitry is illustrated through a discussion of frontotemporal dementia, traumatic brain injury, and sociopathy...
- The evaluation of rapidly progressive dementiaMichael Henry Rosenbloom
Bedford VA Hospital, Geriatric Research and Education Clinical Center GRECC, Bedford
Neurologist 17:67-74. 2011..Jakob-Creutzfeldt disease (CJD) is frequently the most concerning diagnosis on the differential. The challenge for the neurologist is distinguishing prion disease from reversible processes that result in dementia...
- Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distributionM H Rosenbloom
HealthPartner Specialty Center, Center for Dementia and Alzheimer s Care, 401 Phalen Boulevard, Mail Stop 41104C, St Paul, MN 55130, USA
Neurology 76:1789-96. 2011..We sought to compare the distribution of β-amyloid and glucose metabolism in PCA and AD in vivo using Pittsburgh compound B (PiB) and FDG-PET...